SERA Stock Price, Sera Prognostics, Inc. Quote, Chart

Market Summary

USD8.25-0.13

Delayed

-1.55%

SERA Stock Price

View Fullscreen

SERA RSI Chart

SERA Valuation

Market Cap

265.8M

Price/Earnings (Trailing)

-7.87

Price/Sales (Trailing)

868.68

Price/Free Cashflow

-15.26

SERA Price/Sales (Trailing)

SERA Profitability

Return on Equity

-52.16%

Return on Assets

-37.57%

Free Cashflow Yield

-6.55%

SERA Fundamentals

SERA Revenue

Revenue (TTM)

306.0K

Rev. Growth (Yr)

-36.92%

Rev. Growth (Qtr)

-2.38%

SERA Earnings

Earnings (TTM)

-33.8M

Earnings Growth (Yr)

23.36%

Earnings Growth (Qtr)

-2.17%

Breaking Down SERA Revenue

Last 7 days

-10.9%

Last 30 days

-14.8%

Last 90 days

-15.0%

Trailing 12 Months

145.5%

How does SERA drawdown profile look like?

SERA Financial Health

Current Ratio

2.19

SERA Investor Care

Shares Dilution (1Y)

3.87%

Diluted EPS (TTM)

-1.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	330.0K	375.0K	330.0K	306.0K
2022	107.0K	165.0K	229.0K	268.0K
2021	39.3K	53.5K	67.8K	82.0K
2020	0	0	0	25.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Sera Prognostics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	boniface john j.	sold	-221,245	9.04	-24,474	chief scientific officer
Mar 28, 2024	boniface john j.	acquired	22,271	0.91	24,474	chief scientific officer
Mar 27, 2024	boniface john j.	acquired	44,507	0.91	48,909	chief scientific officer
Mar 27, 2024	boniface john j.	sold	-506,608	9.62	-52,662	chief scientific officer
Mar 26, 2024	aerts austin	sold	-75,822	9.37	-8,092	chief financial officer
Mar 26, 2024	lindgardt zhenya	sold	-364,484	9.37	-38,899	chief executive officer
Mar 26, 2024	boniface john j.	sold	-204,733	9.55	-21,438	chief scientific officer
Mar 25, 2024	boniface john j.	sold	-201,683	9.1	-22,163	chief scientific officer
Mar 06, 2024	aerts austin	sold	-4,004	9.02	-444	chief financial officer
Mar 06, 2024	kearney paul	sold	-9,272	9.02	-1,028	chief data officer

Which funds bought or sold SERA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	749	1,049,050	1,137,050	-%
May 16, 2024	AWM Investment Company, Inc.	added	55.95	3,078,530	5,320,440	0.70%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	2,634,050	2,634,050	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	268,648	783,556	0.02%
May 15, 2024	Royal Bank of Canada	added	258	2,000	3,000	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	new	-	1,341,180	1,341,180	-%
May 15, 2024	RA CAPITAL MANAGEMENT, L.P.	new	-	18,420,400	18,420,400	0.23%
May 15, 2024	STATE STREET CORP	added	15.54	294,685	683,337	-%
May 15, 2024	MORGAN STANLEY	added	482	1,259,750	1,419,940	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	sold off	-100	-909,000	-	-%

Are Funds Buying or Selling SERA?

Are funds buying SERA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SERA

No. of Funds

Unveiling Sera Prognostics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 01, 2024	ra capital management, l.p.	6.5%	2,047,221	SC 13G
Feb 13, 2024	vivo capital ix, llc	5.4%	1,650,440	SC 13G/A
Jan 26, 2024	domain partners viii, l.p.	4.3%	1,324,549	SC 13G/A
Jan 19, 2024	interwest partners x lp	0.4%	126,258	SC 13G/A
Jan 10, 2024	baker bros. advisors lp	17.9%	5,434,399	SC 13G
Jan 03, 2024	schindel yair chaim	9.50%	2,978,511	SC 13G/A
Feb 10, 2023	interwest partners x lp	8.5%	2,542,499	SC 13G/A
Jan 09, 2023	schindel yair chaim	6.19%	1,918,511	SC 13G/A
Jul 19, 2022	blue ox healthcare partners, llc	3.4%	0	SC 13G/A
Jun 02, 2022	blue ox healthcare partners, llc	15.4%	0	SC 13G

Recent SEC filings of Sera Prognostics, Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	144	Notice of Insider Sale Intent
May 15, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Sera Prognostics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	196.9B	23.7B	11.04%	17.40%	44.73	8.29	-8.94%	-35.91%
A	45.2B	6.7B	14.64%	19.44%	36.57	6.71	-2.81%	-6.58%
IDXX	44.9B	3.7B	13.71%	10.52%	51.83	12.06	8.57%	23.94%
DGX	16.0B	9.3B	13.66%	10.24%	18.95	1.73	-3.29%	6.68%
NTRA	13.1B	1.2B	17.80%	114.36%	-35.76	10.81	39.26%	33.08%
MEDP	12.2B	2.0B	2.71%	87.82%	38.94	6.2	25.57%	21.62%
CRL	11.4B	4.1B	-3.66%	11.24%	26.02	2.78	0.49%	-11.59%
EXAS	9.3B	2.5B	-20.33%	-38.03%	-38.69	3.67	15.21%	53.51%
MID-CAP
GH	3.1B	603.7M	54.73%	-14.09%	-6.73	5.14	25.21%	30.68%
NEOG	2.9B	929.2M	11.70%	-18.80%	1.9K	3.16	28.93%	111.61%
SMALL-CAP
CDNA	808.3M	275.1M	87.44%	103.94%	-4.41	2.94	-13.93%	-126.97%
ACRS	84.8M	31.1M	-3.25%	-85.34%	-1.1	2.73	0.95%	19.75%
AWH	33.0M	9.2M	-24.07%	-37.65%	-2.24	3.6	11.85%	45.80%
APDN	2.5M	5.5M	-62.31%	120.18%	-0.2	0.45	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Sera Prognostics, Inc. News

Latest updates

Sera Prognostics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	-100.0%	-	41.00	42.00	123	100	65.00	87.00	78.00	38.00	26.00	23.00	20.00	13.00	9.00	5.00	6.00
Operating Expenses	2.3%	9,097	8,889	8,226	11,583	11,429	10,483	11,275	11,824	12,338	12,573	9,465	7,401	6,038	-	4,649	4,287
S&GA Expenses	-5.9%	1,227	1,304	1,355	2,872	2,818	3,055	2,967	4,219	4,458	4,548	2,690	1,740	1,350	-	1,054	712
R&D Expenses	-5.4%	3,683	3,895	3,539	3,688	4,103	3,485	4,176	3,261	3,322	3,075	2,724	2,824	2,396	-	1,888	1,752
Interest Expenses	-18.2%	9.00	11.00	14.00	14.00	16.00	5.00	21.00	18.00	4.00	444	439	-2.00	307	-	-	-
Net Income	-2.2%	-8,097	-7,925	-7,210	-10,542	-10,565	-9,746	-10,712	-11,520	-12,208	-12,484	-9,859	-6,307	-6,359	-5,375	-5,072	-4,705
Net Income Margin	6.8%	-110.37*	-118.44*	-115.34*	-110.84*	-128.92*	-164.87*	-204.91*	-279.22*	-381.85*	-426.94*	-411.81*	-432.02*	-548.05*	-793.92*	-	-
Free Cashflow	173.4%	4,979	-6,781	-7,620	-7,995	-4,920	-7,431	-9,149	-9,257	-9,564	-9,901	-9,725	-6,323	-6,991	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-5.8%	90.00	95.00	90.00	97.00	106	116	117	125	135	147	154	95.00	15.00
Current Assets	-12.2%	54.00	61.00	48.00	64.00	72.00	90.00	91.00	108	109	110	122	91.00	14.00
Cash Equivalents	9.3%	4.00	4.00	10.00	32.00	27.00	30.00	39.00	54.00	64.00	59.00	82.00	91.00	14.00
Net PPE	-	-	-	-	-	-	-	-	-	-	2.00	1.00	1.00	1.00
Liabilities	-0.6%	25.00	25.00	15.00	16.00	15.00	17.00	9.00	8.00	8.00	8.00	4.00	4.00	12.00
Current Liabilities	0.5%	25.00	24.00	14.00	14.00	14.00	16.00	9.00	7.00	7.00	8.00	4.00	3.00	11.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	4.00
Shareholder's Equity	-7.7%	65.00	70.00	75.00	81.00	90.00	99.00	107	117	127	139	150	-	-
Retained Earnings	-3.3%	-254	-246	-239	-231	-221	-210	-200	-190	-178	-166	-154	-144	-131
Additional Paid-In Capital	0.9%	320	317	315	314	312	311	309	308	307	305	304	8.00	6.00
Shares Outstanding	3.3%	32.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	15.00	25.00	2.00	2.00
Float	-	-	-	-	92.00	-	-	-	39.00	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	173.8%	4,994	-6,765	-7,594	-7,948	-4,881	-7,238	-8,777	-9,038	-9,557	-9,152	-9,296	-6,238	-6,950	-	-	-
Share Based Compensation	25.7%	1,693	1,347	1,182	1,440	1,304	1,341	1,278	1,214	1,222	1,113	914	864	239	-	-	-
Cashflow From Investing	-1621.1%	-5,689	374	-15,164	12,908	2,320	-1,578	-6,296	-1,209	14,634	-14,432	-68,001	-85.00	-41.00	-	-	-
Cashflow From Financing	71.1%	1,054	616	128	124	-116	-116	-8.00	58.00	71.00	37.00	68,925	37,158	53,474	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SERA Income Statement

2024-03-31

Condensed Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 0	$ 100
Operating expenses:
Cost of revenue	17	62
Research and development	3,683	4,103
Selling and marketing	1,227	2,818
General and administrative	4,170	4,446
Total operating expenses	9,097	11,429
Loss from operations	(9,097)	(11,329)
Interest expense	(9)	(16)
Other income, net	1,009	780
Net loss	$ (8,097)	$ (10,565)
Net loss per share, basic (in usd per share)	$ (0.25)	$ (0.34)
Net loss per share, diluted (in usd per share)	$ (0.25)	$ (0.34)
Weighted-average shares of common stock outstanding, basic (in shares)	32,220,038	31,019,311
Weighted-average shares of common stock outstanding, diluted (In shares)	32,220,038	31,019,311
Other comprehensive income (loss):
Unrealized (loss) gain on available-for-sale debt securities, net of tax	$ (166)	$ 524
Total other comprehensive (loss) income	(166)	524
Comprehensive loss	$ (8,263)	$ (10,041)

SERA Balance Sheet

2024-03-31

Condensed Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 4,239	$ 3,880
Marketable securities	48,734	45,199
Accounts receivable	117	160
Other receivables	0	11,310
Prepaid expenses and other current assets	756	795
Total current assets	53,846	61,344
Property and equipment, net	1,808	1,999
Long-term marketable securities	32,386	30,841
Other assets	1,846	1,257
Total assets	89,886	95,441
Current liabilities:
Accounts payable	1,026	1,046
Accrued and other current liabilities	2,863	2,722
Finance lease obligation, current portion	448	440
Deferred revenue	20,231	20,235
Total current liabilities	24,568	24,443
Finance lease obligation, net of current portion	81	196
Long-term portion	487	644
Total liabilities	25,136	25,283
Commitments and Contingencies
Stockholders' equity:
Common stock, $0.0001 par value; 150,000,000 Class A shares authorized; 31,599,582 and 30,736,513 Class A shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively; 1,500,000 Class B shares authorized; 1,405,259 Class B shares issued as of March 31, 2024 and December 31, 2023; 967,759 Class B shares outstanding as of March 31, 2024 and December 31, 2023.	3	3
Additional paid-in capital	319,921	317,066
Accumulated other comprehensive loss	(181)	(15)
Accumulated deficit	(254,993)	(246,896)
Total stockholders' equity	64,750	70,158
Total liabilities and stockholders' equity	$ 89,886	$ 95,441

About Sera Prognostics, Inc.

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

CEO	Ms. Evguenia Lindgardt M.B.A.
WEBSITE	https://seraprognostics.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	87

Sera Prognostics, Inc. Frequently Asked Questions

What is the ticker symbol for Sera Prognostics, Inc.? What does SERA stand for in stocks?

SERA is the stock ticker symbol of Sera Prognostics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sera Prognostics, Inc. (SERA)?

As of Fri May 17 2024, market cap of Sera Prognostics, Inc. is 265.82 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SERA stock?

You can check SERA's fair value in chart for subscribers.

What is the fair value of SERA stock?

You can check SERA's fair value in chart for subscribers. The fair value of Sera Prognostics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sera Prognostics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SERA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sera Prognostics, Inc. a good stock to buy?

The fair value guage provides a quick view whether SERA is over valued or under valued. Whether Sera Prognostics, Inc. is cheap or expensive depends on the assumptions which impact Sera Prognostics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SERA.

What is Sera Prognostics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, SERA's PE ratio (Price to Earnings) is -7.87 and Price to Sales (PS) ratio is 868.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SERA PE ratio will change depending on the future growth rate expectations of investors.